Downregulation of CDC20 suppressed cell proliferation, induced apoptosis, triggered cell cycle arrest in osteosarcoma cells, and enhanced chemosensitivity to cisplatin
Related Experiment Video
Updated: Dec 3, 2025
Yi Gao1,2, Caili Guo1,2, Shuqin Fu1,2
1Department of Acute and Critical Care Medicine, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou, China.
Abstract:
Osteosarcoma (OS) is a common malignant bone tumor that occurs in adolescents or children under the age of 20, which is extremely difficult to cure and has a high recurrence rate. Recent studies showed that cell division cycle 20 (CDC20) overexpression is associated with poor prognosis in patients with osteosarcoma. However, the function of CDC20 in osteosarcoma has not been investigated clearly. In this study, we aim to explore the role of CDC20 in two independent human OS cell lines' biological phenotype and chemotherapy sensitivity. We applied multiple approaches to measure cell growth, cell cycle, and apoptosis with or without deregulation or overexpression of CDC20. We found that the downregulation of CDC20 by siRNA or apcin suppressed cell proliferation, induced apoptosis, and triggered cell cycle arrest. Consistently, overexpression of CDC20 in normal cells promoted cell growth, inhibited apoptosis. What's more, the additional treatment with siCDC20 or Apcin achieved better anticancer effects than that of cisplatin alone. Furthermore, Bim and p21 were upregulated in OS cells following Apcin treatment. Altogether, the results of the present study demonstrated that targeting CDC20 could be useful for the treatment of OS, and might be a promising solution for the treatment of the OS with cisplatin insensitivity.
Insights
Targeting cell division cycle 20 (CDC20) shows promise for treating osteosarcoma (OS). Inhibiting CDC20 suppresses tumor growth and enhances chemotherapy effectiveness, offering new hope for difficult-to-cure bone cancers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Osteosarcoma (OS) is a challenging bone cancer with high recurrence rates, particularly in adolescents.
- Overexpression of cell division cycle 20 (CDC20) correlates with poor prognosis in OS patients.
- The precise role of CDC20 in OS progression and treatment remains unclear.
Purpose of the Study:
- To investigate the function of CDC20 in human osteosarcoma cell lines.
- To evaluate the impact of CDC20 modulation on OS cell proliferation, cell cycle, and apoptosis.
- To assess the potential of targeting CDC20 to improve chemotherapy sensitivity in OS.
Main Methods:
- Utilized siRNA and apcyn to downregulate CDC20 expression in OS cells.
- Overexpressed CDC20 in normal cells for comparative analysis.
- Assessed cell proliferation, cell cycle progression, and apoptosis using various assays.
- Evaluated the combined effects of CDC20 inhibition and cisplatin treatment.
Main Results:
- Downregulation of CDC20 inhibited OS cell proliferation, induced apoptosis, and caused cell cycle arrest.
- CDC20 overexpression promoted cell growth and inhibited apoptosis in normal cells.
- Combined treatment with CDC20 inhibitors (siCDC20 or Apcin) and cisplatin showed enhanced anticancer effects compared to cisplatin alone.
- Apcin treatment led to upregulation of Bim and p21 in OS cells.
Conclusions:
- Targeting CDC20 is a potentially effective therapeutic strategy for osteosarcoma.
- Modulating CDC20 can overcome cisplatin resistance in OS.
- CDC20 inhibition represents a promising approach for improving OS treatment outcomes.
Related Concept Videos
Inhibition of Cdk Activity
Negative Regulator Molecules
Abnormal Proliferation
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Molecular Factors Affecting Cell Division
Several proteins function as internal regulators to ensure each cell cycle stage is completed faithfully before proceeding to the next. Regulator molecules may act directly or influence the activity or production of other...


